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Is the Horse Already Out of the Barn?*Christine M. Albert, MD, MPHI t is estimated that 2.3 million Americans ex-perience atrial ﬁbrillation (AF), and on the basisof documented increases in AF prevalence and
incidence in U.S. population-based studies, this num-
ber may increase to anywhere from 5.6 million (1) to
as much as 15.9 million by 2050 (2). Recent estimates
suggest that over 10% of the population will develop
AF by age 75 years (2). Once AF develops, pharmaco-
logical and invasive treatments aimed at eliminating
AF and maintaining sinus rhythm have signiﬁcant
risks, limited long-term success rates, and have not
been documented to reduce adverse outcomes associ-
ated with AF (3,4). Therefore, there is a pressing need
for novel, safer therapies to not only treat established
AF, but also to prevent incident AF and AF-related
morbidity and mortality.
Pharmacological therapy for AF has traditionally
centered on cardiac ion channel blockers, which dir-
ectly alter cellular electrophysiology to suppress AF,
but have little impact on the development of the atrial
substrate involved in the initiation andmaintenance of
AF (5). In addition, these drugs are limited by incom-
plete effectiveness and the risk of life-threatening
proarrhythmic complications. As a result, there has
been signiﬁcant interest in evaluating “upstream”
therapies (6) that might alter the atrial substrate
without inducing proarrhythmia. Long-chain n-3
polyunsaturated fatty acids (PUFAs) not only have
multiple direct and indirect effects on cardiac*Editorials published in the Journal of the American College of Cardiology
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effects of n-3 PUFA and vitamin D supplementation on atrial ﬁbrillation.electrophysiology (7,8), but they also have autonomic,
antiﬁbrotic, anti-inﬂammatory, and antioxidant pro-
perties that have the potential to alter atrial structural
and electrical properties involved in the initiation
and maintenance of AF (5,9). On this basis, along with
observational evidence suggesting a possible link be-
tween blood levels of long-chain n-3 PUFAs and the
development of incident AF (10,11), randomized trials
have been conducted to test the efﬁcacy of these
nutritional supplements as therapeutic agents in AF.
To date, randomized trials of n-3 PUFAs with AF as
the primary endpoint have either examined recurrent
AF events in patients with established AF or short-
term AF development in patients undergoing car-
diac surgery. Trials have involved heterogeneous
patient populations, diverse designs, different n-3
PUFA dosages and formulations, and relatively
small sample sizes. Some of the smaller trials de-
monstrated signiﬁcant reductions in AF recurrence
after cardioversion and postcardiac surgery (12–14),
which have not been conﬁrmed in recent larger trials
(15–17). When the results of these diverse trials are
combined in a meta-analysis, pooled risk estimates
are null for AF recurrence in established AF patients
(relative risk: 0.95; 95% conﬁdence interval: 0.79 to
1.13) and for postoperative AF (relative risk: 0.86; 95%
conﬁdence interval: 0.71 to 1.04), with marked sta-
tistical heterogeneity observed between trials,
particularly for recurrent AF (17).SEE PAGE 1441In this issue of the Journal, Nigam et al. (18) report
the results of another secondary prevention trial, the
AFFORD (Multi-center Study to Evaluate the Effect of
N-3 Fatty Acids [OMEGA-3] on Arrhythmia Recur-
rence in Atrial Fibrillation), a double-blind, random-
ized, placebo-controlled trial of ﬁsh oil (4 g/day,
docosahexaenoic acid [DHA]: eicosapentaenoic acid
[EPA] 1:2) versus safﬂower oil placebo in 337 patients
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1450with symptomatic paroxysmal or persistent AF. The
primary endpoint of AFFORD was time to ﬁrst
asymptomatic or symptomatic AF recurrence lasting
>30 s over a follow-up period of up to 16 months.
Patients taking antiarrhythmic drugs were excluded,
and weekly transtelephonic transmissions were used
to screen for asymptomatic AF. The trial documented
a high AF recurrence rate in this study group (63%),
with a shorter time to ﬁrst AF recurrence in the ﬁsh oil
group, which did not reach statistical signiﬁcance
(p ¼ 0.08). There were no signiﬁcant differences be-
tween the randomized treatment arms in the sec-
ondary endpoints of inﬂammatory (high-sensitivity
C-reactive protein) or oxidative stress (myeloperox-
idase) markers measured at baseline and after treat-
ment at 6 months. n-3 PUFA levels in this population
were fairly high at baseline, but increased signiﬁ-
cantly to the levels where beneﬁts for incident AF
have been suggested by observational studies (10,11).
However, in contrast to these population-based
studies, no relationship between n-3 PUFA levels
and recurrent AF was observed in the secondary
prevention population enrolled in AFFORD.
Despite the relatively small sample size, there
are several important strengths of AFFORD that
address concerns raised regarding design aspects of
previous clinical trials, which could have led to
false-negative results. First, AFFORD used a 3-week
loading run-in phase before accruing endpoints,
which should have allowed substantial, albeit not
full, incorporation of n-3 PUFAs into myocardial
membranes (19). In the largest secondary prevention
trial to date involving 663 patients (15), nearly half of
the AF events occurred during the ﬁrst 28 days of
treatment before the time when n-3 PUFA levels
reach a steady state in the atrium (19). The AFFORD
also excluded patients taking antiarrhythmic drugs
and was the ﬁrst to use transtelephonic monitoring
to document asymptomatic AF events, which resul-
ted in a higher and more complete AF ascertainment
than previous trials. The clinical signiﬁcance of brief
AF events detected by monitoring is unknown, but
recent data in pacemaker patients suggest that epi-
sodes lasting only 6 min are associated with an
increased stroke risk (20). Previous trials also had
relatively short-term follow-up of 6 months to 1 year,
which may not have been adequate for n-3 PUFAs to
have a major impact on the process of atrial remod-
eling (9). The AFFORD followed some patients for as
long as 16 months; however, the majority of events in
the AFFORD still occurred in the ﬁrst 3 months of the
study, with few patients followed beyond 1 year.
Finally, in contrast to studies of postoperative AF
(21), the AFFORD did not ﬁnd major increases inselected markers of inﬂammatory or oxidative stress,
and these markers were not affected by n-3 PUFA
supplementation.
Is the AFFORD the “ﬁnal nail in the cofﬁn” on the
use of n-3 PUFAs for AF or is “the horse already out
of the barn” in these patients with established AF?
Clearly, these data, in combination with data from
previous randomized trials, do not support the practice
of using n-3 PUFAs as a substitute for antiarrhythmic
drugs to prevent recurrent AF events. However, given
the potential pleiotropic actions of n-3 PUFAs, it is
quite plausible that these agents might be more effec-
tive at preventing, rather than reversing, the devel-
opment of the atrial substrate associated with AF and/
or that longer term therapy may be required to have
a signiﬁcant impact on atrial remodeling in patients
with established AF. Therefore, important beneﬁts
for AF risk could be missed in these short-term sec-
ondary prevention trials, whichmight only be detected
in longer term and/or primary prevention trials.
Also, the mechanistic complexities of n-3 PUFAs (8)
and of the substrates that underlie AF (5) need to be
considered. n-3 PUFAs have multiple actions that may
both promote and prevent AF in different clinical
scenarios, and their actions may vary with the base-
line dietary intake of n-3 PUFAs. Observational
studies examining the association between dietary
intake of long-chain n-3 PUFAs and incident AF have
been mixed, with some studies suggesting beneﬁt,
others neutrality, and others raising the possibility of
risk (8). Given the signiﬁcant proportion of the pop-
ulation already taking ﬁsh oil supplements (22), a
better understanding of the long-term effects of these
supplements on AF in large populations is needed.
The VITAL (VITamin D and OmegA-3 TriaL) Rhythm
Substudy is currently examining the impact of ran-
domized treatment with 1 g/day of n-3 PUFAs on
incident AF events in 25,875 men and women without
cardiovascular disease over 5 years of follow-up. It is
hoped that studies such as this, with planned long-
term treatment and follow-up for AF events, will
provide much-needed data beyond those available
from observational studies to determine the summa-
tion of beneﬁts and risks of these agents on AF inci-
dence and recurrence in the general population. At
present, n-3 PUFA supplements cannot be recom-
mended on the basis of the available data as thera-
peutic agents to prevent recurrent or incident AF.
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